Kiniksa Pharmaceuticals International, plc
KNSA
Rangering i aksjer
#2877
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aksjekurs
$83.13
Sist synkronisert: 2026-10-20
Markedsverdi
$6.49B
Endring (1 dag)
4.59%
Endring (1 år)
113.97%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Antall utestående aksjer for Kiniksa Pharmaceuticals International, plc (KNSA)
Antall utestående aksjer per June 2026: 77.58M
Ifølge Kiniksa Pharmaceuticals International, plc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 77.58M. Ved slutten av December 2023 hadde selskapet 70.06M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Kiniksa Pharmaceuticals International, plc (KNSA) fra 2016 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 77.58M | 8.62% |
| 2024 | 71.42M | 1.95% |
| 2023 | 70.06M | 0.98% |
| 2022 | 69.38M | 1.17% |
| 2021 | 68.58M | 10.89% |
| 2020 | 61.84M | 14.42% |
| 2019 | 54.05M | 82.92% |
| 2018 | 29.55M | -8.99% |
| 2017 | 32.47M | 0.00% |
| 2016 | 32.47M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 445.06M | 473.70% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 105.38M | 35.83% |
US
|
